Impacto presupuestario de XEN®63 en el tratamiento del glaucoma primario de ángulo abierto en España

  1. Jorge Vila-Arteaga 1
  2. Esperanza Gutiérrez-Díaz 2
  3. José María Martínez-De-La-Casa 3
  4. E. Millá Griñó 4
  5. Almudena Asorey-García 5
  6. J. Salvador Alepuz 6
  7. C. de Miguel González 7
  8. R. Palomino Meneses 7
  9. E. Uría Mundo 7
  1. 1 Hospital Universitario La Fe
    info

    Hospital Universitario La Fe

    Valencia, España

    ROR https://ror.org/01ar2v535

  2. 2 Hospital Universitario 12 de Octubre
    info

    Hospital Universitario 12 de Octubre

    Madrid, España

    ROR https://ror.org/00qyh5r35

  3. 3 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  4. 4 Hospital Clinic Barcelona
    info

    Hospital Clinic Barcelona

    Barcelona, España

    ROR https://ror.org/02a2kzf50

  5. 5 AbbVie Spain, S.L.U
  6. 6 Former AbbVie employee
  7. 7 Market Access Area, Pharmalex Spain, Barcelona, España
Show affiliations +
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2023

Volume: 98

Issue: 1

Pages: 2-10

Type: Article

DOI: 10.1016/J.OFTAL.2022.09.004 DIALNET GOOGLE SCHOLAR

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Background and objective To evaluate the economic impact in Spain derived from the introduction of the XEN®63 implant as a surgical alternative in the management of primary open angle glaucoma (POAG) with or without cataract in refractory patients. Materials and methods A budget impact analysis was designed to estimate the costs of surgical treatment of POAG from the perspective of the Spanish National Health System (NHS), over a time horizon of 1 year. The comparators considered (trabeculectomy, deep non-perforating sclerectomy, Ahmed valve, iStent inject®, Preserflo® microshunt and XEN®45) correspond to those used in Spanish public clinical practice. For the calculation of the target population, market shares and resource use in terms of follow-up visits, additional procedures and post-surgery complications, data from the literature were used and validated with a panel of 4 experts. Unit costs (€2021) were obtained from the ESALUD database. Results The inclusion of XEN®63 could generate savings of €2,569,737 after one year since its introduction, derived from savings in the cost of the implant and procedure (−€423,120; −0.7%), follow-up visits (−€777,407; −4.5%), additional procedures (−1,048,145; −20.6%) and post-surgery complications (−€321,065; −14.2%). Conclusions The incorporation of XEN®63 in the surgical arsenal for the treatment of refractory POAG with and without cataracts could generate savings for the NHS.

Data source: Dialnet